Print

IGBA letter to FDA regarding their biologics naming proposals

The International Generic and Biosimilar Medicines Association (IGBA), representing member associations from the U.S. (GPhA), Canada (CGPA), Japan (JGA), Jordan (JAPM), Europe (EGA), South Africa (NAPM), and Taiwan (TGPA), as well as associate member associations from Australia (GBMA), Brazil (ProGenericos) and Mexico (AMEGI), thank for the opportunity to share our thoughts on the important topic of non-proprietary naming of biological products, including biosimilar products.

Print

IGBA Welcomes ICH Reform and Openness For New Members

JOHANNESBURG, SOUTH AFRICA (November 3, 2015).- The International Generic and Biosimilar Medicines Association (IGBA) welcomed the International Conference on Harmonisation (ICH) reform and the opening of the process to new members, including international industry organisations. The IGBA fully recognises the contribution of the ICH in developing international standards applied to the pharmaceutical industry, including generic and biosimilar manufacturers.

Print

IGPA becomes IGBA and chairmanship shifts to South Africa

TORONTO, CANADA (October 13, 2015).- Jim Keon, President of the Canadian Generic Pharmaceutical Association (CGPA) and Chair of the IGBA, announced at the IGBA Conference in Toronto that the International Generic and Biosimilar Medicines Association (IGBA) will register as an association in Geneva, Switzerland. The legal incorporation strengthens existing informal links with international institutions such as the World Trade Organization (WTO), the World Health Organization (WHO) and the World Intellectual Property Organization (WIPO).

Share this page!

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

C/O DYN SA
Rue de Cornavin 11
1201 Geneva, Switzerland

E-mails: 
This email address is being protected from spambots. You need JavaScript enabled to view it.  
or  
Secretary General –   This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow us on: Twitter - LinkedIn - YouTube

We use cookies to improve our website and your experience when using it. Cookies used for the essential operation of the site have already been set. To find out more about the cookies we use and how to delete them, see our Privacy Policy.

I accept cookies from this site